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Objectives: This article introduces a series of articles on antibiotic consumption in the community between 1997
and 2017, which provide an update of previous articles covering the periods 1997–2003 and 1997–2009.
Methods: In this article, differences in participating countries, the ATC/DDD classification system, and data col-
lection, validation and analysis between the current and previous series are described.
Results: In the previous series, 33 European countries provided valid data for further analysis, while the current
series focused on 30 countries belonging to the EU or the European Economic Area (EEA). For both series, data
were collected in accordance with the WHO ATC classification system. While the previous series reported data in
accordance with the ATC/DDD index 2011, the current series employed the ATC/DDD index 2019. Both series
focused on consumption of antibacterials for systemic use (ATC J01) and collected data expressed in DDD per
1000 inhabitants per day and packages per 1000 inhabitants per day. When studying consumption expressed in
packages per 1000 inhabitants per day, countries reporting total care data, i.e. community and hospital sector
combined, were included in the previous series but excluded in the current series. While the previous series used
non-linear mixed models to evaluate time trends in antibiotic consumption, the current series allowed for inclu-
sion of change-points with a data-driven location. In addition, both series assessed the composition and quality
of antibiotic consumption in the EU/EEA.
Conclusions: The updated analyses of two decades of ESAC-Net data provide the most comprehensive and
detailed description of antibiotic consumption in the community in Europe.
Introduction
Antibiotics are medicines that are used to treat bacterial infections.
Over time, their use and misuse have led to antimicrobial resist-
ance resulting in treatment failure, increased costs of care and
an elevated risk of mortality.1 In order to fight this worldwide
public health problem, trustworthy information on antibiotic
consumption is essential. In 2001, an international network of
surveillance systems collecting comparable and reliable data on
antimicrobial consumption in Europe — the European Surveillance
of Antimicrobial Consumption (ESAC) project — was launched to ac-
company analogous surveillance on antimicrobial resistance.2 By
2009, the ESAC project had expanded to a network of 35 European
countries, including 28 EU Member States, 3 European Economic
Area (EEA)/European Free Trade Association countries (Iceland,
Norway and Switzerland), a candidate country (North Macedonia)
and 3 other countries (Israel, the Russian Federation and Turkey). In
2011, ECDC took over the coordination of the collection of data on
antimicrobial consumption from EU/EEA countries as the European
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Surveillance of Antimicrobial Consumption Network (ESAC-Net),3
which covers all EU/EEA countries in agreement with Decision
No. 1082/2013/EU of the European Parliament and the Council on
serious cross-border threats to health.4 Information on antimicro-
bial consumption in the EU/EEA is publicly accessible through an
interactive database and annual reports.5
This article introduces a series of articles on antibiotic consump-
tion in the community in the EU/EEA, which provides an update
of previous articles covering the periods 1997–20036–10 and
1997–2009.11–17 In this series, we update the results of previously
published brief reports focusing on antibacterials for systemic use,
penicillins, cephalosporins, macrolides-lincosamides-streptogra-
mins, quinolones, tetracyclines, sulphonamides and trimethoprim,
and other antibacterials, as well as on indicators to assess the
quality of antibiotic consumption in the community.18–24 We refer
to community rather than outpatient or ambulatory consumption
to stress our focus on primary care, and not hospital care, provided
through prescriptions by general practitioners and other special-
ized doctors in community practices. Prescriptions in long-term
care facilities and nursing homes, for outpatient parenteral anti-
microbial therapy and in rehabilitation centres are all part of the
community sector.25 We also add recent data and update the
results applying the ATC/DDD index 2019,26 including relevant
changes for the most commonly prescribed antibiotic substances.
In addition, we have improved the longitudinal data analyses by
allowing for change-points with a data-driven location.27
Current (1997–2017) versus previous
(1997–2009) series
Because several aspects regarding the data collection and analysis
have changed when compared with the previous series of articles,
we summarize the differences between the current and the
previous series in the following paragraphs.
Participants
In the previous series (1997–200911–17), 33 European countries
provided valid data for further analysis and all were included ex-
cept North Macedonia and Turkey. In this series, we focused on the
30 countries belonging to the EU (28 countries) or the EEA (Iceland
and Norway) that contributed data to ESAC-Net during 1997–2017
(Figure 1).
ATC/DDD classification system
For both series of articles, data on the consumption of antibacteri-
als for systemic use (ATC J01) in the community were collected in
accordance with the WHO ATC classification. However, while the
previous series reported data in accordance with the ATC/DDD
index 2011,28 the current series reports data in accordance with
the ATC/DDD index 2019.26 While the WHO aims to keep changes
in DDDs to an absolute minimum, several important changes were
implemented to better approximate the daily doses prescribed in
practice. In 2017, the DDD changed for parenteral ampicillin/sul-
bactam (J01CR01, from 2 g to 6 g). In 2019, the DDD changed for
parenteral ampicillin (J01CA01, from 2 g to 6 g), oral amoxicillin
(J01CA04, from 1 g to 1.5 g), parenteral amoxicillin (J01CA04, from
1 g to 3 g), parenteral temocillin (J01CA17, from 2 g to 4 g), oral
amoxicillin/clavulanic acid (J01CR02, from 1 g to 1.5 g), parenteral
cefepime (J01DE01, from 2 g to 4 g), parenteral meropenem
(J01DH02, from 2 g to 3 g), parenteral ciprofloxacin (J01MA02,
from 0.5 g to 0.8 g), and parenteral colistin (J01XB01, from 3 MU to
9 MU). These changes (increases) in DDD values (e.g. for oral
Figure 1. Map of Europe showing the 30 EU/EEA countries included in the series of articles. Blue colour indicates countries included in both the longi-
tudinal (quarterly consumption) and the compositional (yearly consumption) data analysis, and purple colour indicates countries included only in the
compositional data analysis. Map created using https://mapchart.net/europe.html.
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amoxicillin, from 1 g to 1.5 g) result in a lower number of DDDs per
package (e.g. for oral amoxicillin, from 21 DDD to 14 DDD for a
package containing 21 amoxicillin units of 1 g) and lower con-
sumption when expressed in DDD per 1000 inhabitants per day.
Both series of articles focused on antibacterials for systemic use
(ATC J01, excluding topical antibiotics), which consists of 10 groups
(ATC-3 level) and 33 subgroups (ATC-4 level). While 229 unique
chemical substances (ATC-5 level) were assigned an ATC code
at the time the data for the previous series were collected,
259 unique chemical substances were assigned an ATC code at
the time the data for the current series were collected.
Data collection
The previous series of articles was based on data for 1997–2009
collected by the ESAC project, for which countries were asked to
deliver data at product level, i.e. using a unique identifier for each
of the medicinal product packages available in their country.
Information on the number of packages consumed for each prod-
uct had to be accompanied by an exhaustive and valid national
register file including information on the number of DDD in each
unique package.
The current series is based on data for 1997–2017 retrieved
from The European Surveillance System (TESSy29) in which ESAC-
Net data are stored (export date 26 June 2019). In this system,
countries have two options for reporting antibiotic consumption
data: either at product level or as aggregate numbers of DDDs
consumed for each chemical substance (ATC-5 level) without the
requirement to include information on package size. Data covering
the period 1997–2009 were uploaded into TESSy after termination
of the ESAC project.
When considering the most recent antibiotic consumption
data, 2009 data were not reported for Switzerland in the previous
series, and 2017 data were not reported for Czechia and Slovakia
in the current series. In both series of articles, data from the last
available year were used instead. In the previous series, 2004 data
were used for Switzerland, and in the current series 2015 data
were used for Czechia and 2016 data for Slovakia.
Data description
Information on data source, coverage and, if available, online pub-
lication of national antibiotic consumption data were also col-
lected (Table S1, available as Supplementary data at JAC Online).
Most countries provided data from the same source in both series:
16 countries reported sales data, 6 reported reimbursement data
and 2 reported data based on sales and reimbursement informa-
tion (Italy and Slovenia). However, Croatia and Portugal reported
sales data in the previous series and reimbursement data in
the current series; Hungary, Poland and Romania reported reim-
bursement data in the previous series and sales data in the current
series; and Spain reported reimbursement data in the previous
series and data based on sales and reimbursement information in
the current series. Sales data were based on reports from pharma-
ceutical companies, wholesalers, pharmacies or marketing re-
search companies. Reimbursement data were collected by the
third-party payer on the basis of financial claims from legitimate
beneficiaries.
Antibiotic consumption was expressed in DDD per 1000 inhabi-
tants per day, and if possible also in packages per 1000 inhabitants
per day. Annual antibiotic consumption expressed in DDD per 1000
inhabitants per day was available for 30 countries overall and 28
countries in 2017 (all but Czechia and Slovakia). Annual antibiotic
consumption expressed in packages per 1000 inhabitants per day
was available for 25 countries overall (all but Germany, Hungary,
Malta, Norway and Poland) and for 20 of these countries in 2017
(all but Czechia, Luxembourg, the Netherlands, Slovakia and the
United Kingdom). The number of DDD per package was calculated
by dividing antibiotic consumption expressed in DDD per 1000
inhabitants per day by antibiotic consumption expressed in pack-
ages per 1000 inhabitants per day for each subgroup (ATC-3 level).
In this comparison, countries (or time-points) reporting total care
data, i.e. aggregated consumption data reported for the commu-
nity and hospital sector combined, were included in the previous
series (e.g. Lithuania), but excluded in the current series (e.g.
Romania, Bulgaria 1999–2005). Antibiotic consumption data are
reported through annual data calls with the option to report quar-
terly data. Quarterly data expressed in DDD per 1000 inhabitants
per day were available for 25 countries (all but Bulgaria, France,
Malta, Norway and Romania).
In most of the participating countries, the denominator was
provided as the WHO mid-year population in the previous series
and by Eurostat in the current series.30 Some countries provided
denominator data from their national statistical office (France,
Germany, Portugal, Spain and Sweden for both series; Cyprus and
the United Kingdom only for the previous series; Croatia, Czechia,
Iceland, Lithuania and Slovenia only for the current series).
Another possible source for denominator data was the insured
population (Luxembourg for both series).
Data coverage for both series of articles was 100% for most
countries. In the previous series, exceptions were Belgium (98%),
Germany (90%), the Netherlands (90%), and Portugal (77%), and
data for Luxembourg covered 100% of only the insured popula-
tion. In the current series, exceptions were Belgium (99%), the
Netherlands (93%) and Germany (85%), and data for Luxembourg
covered 90% of only the insured population.
Some countries were only able to provide total care data, i.e.
community and hospital sector combined. For all series including
the current series, this concerned Bulgaria (up to 2005), Cyprus (be-
tween 2006 and 2017), Estonia (in 2001), Greece (between 2004
and 2010), Iceland (up to 2005 and between 2010 and 2013),
Lithuania (up to 2011), Romania (between 2011 and 2017) and
Slovakia (in 2011). These data were included because the vast ma-
jority of total care data represents community consumption
(results not presented).
Data validation
A software application was used to upload country data to the
core database, i.e. ESAC Collect Manager Application for the previ-
ous series and The European Surveillance System (TESSy) for the
current series. Both generated a standard validation report, which
was sent for approval to country representatives, i.e. the ESAC lead
national representative for the previous series and the ECDC
National Focal Points for antimicrobial consumption and related
Operational Contact Points nominated by the countries for the cur-
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can be found in the ESAC Yearbooks31 and in the ESAC-Net
Reporting Protocols.32
Analysis
As in the previous series,11–16 the EU/EEA ranking of consumption
of antibiotics in the last reported year and expressed in DDD per
1000 inhabitants per day was presented. For countries that did not
report antibiotic consumption in 2017, antibiotic consumption in
the last available year was shown (2015 for Czechia and 2016 for
Slovakia). If countries also reported antibiotic consumption
expressed in packages per 1000 inhabitants per day, this ranking
was presented as well. To facilitate a better understanding of the
difference in these rankings, the number of DDD per package was
presented. The evolution of the number of DDD per package over
time was assessed using a linear mixed model, with the optimal
model selected based on the Akaike Information Criterion.33,34
To evaluate the time trend and seasonal variation in antibiotic
consumption from 1997 to 2017 in EU/EEA countries, quarterly
data expressed in DDD per 1000 inhabitants per day were mod-
elled with a non-linear mixed model including a sine wave, as
applied and described in a tutorial article by Minalu et al.35 To im-
prove model fit, we turned to a Bayesian framework that allows for
the inclusion of change-points with a data-driven location in the
current series.36 A practical overview of this approach, as well as its
limitations, is provided in a tutorial article.27 Similar to the last ser-
ies of articles, compositional data analysis was used to model an-
nual antibiotic consumption expressed in DDD per 1000
inhabitants per day in order to assess trends of the relative propor-
tions of the main antibiotic subgroups from 1997 up to 2017 for
EU/EEA countries.37
In addition, the quality of antibiotic consumption in the com-
munity (EU/EEA countries, 2017) was assessed through 12 ESAC
drug-specific quality indicators,38 as in the previous series.17 In the
current series, an ECDC/EFSA/EMA joint scientific indicator was
added.39
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